EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Probing the Biosafety of Implantable Artificial Secretory Granules for the Sustained Release of Bioactive Proteins

Patricia Álamo, Eloi Parladé iD, Marianna T P Favaro, Alberto Gallardo, Rosa Mendoza, Luís C S Ferreira, Nerea Roher, Ramón Mangues, Antonio Villaverde iD, Esther Vázquez

ACS Applied Materials & Interfaces · 2023

DOI: 10.1021/acsami.3c08643 ↗

At a glance

Journal article in ACS Applied Materials & Interfaces, 2023. Written by Patricia Álamo and 9 co-authors. Institution: Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), 08041 Barcelona, Spain. Major MEDLINE topics: Containment of Biohazards, COVID-19. Cited 6 times so far (Crossref); 72 references. The full text is freely available (open access, CC BY 4.0). Funded by: Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Among bio-inspired protein materials, secretory protein microparticles are of clinical interest as self-contained, slow protein delivery platforms that mimic secretory granules of the human endocrine system, in which the protein is both the drug and the scaffold. Upon subcutaneous injection, their progressive disintegration results in the sustained release of the building block polypeptides, which reach the bloodstream for systemic distribution and subsequent biological effects. Such entities are easily fabricated in vitro by Zn-assisted cross-molecular coordination of histidine residues. Using cationic Zn for the assembly of selected pure protein species and in the absence of any heterologous holding material, these granules are expected to be nontoxic and therefore adequate for different clinical uses. However, such presumed biosafety has not been so far confirmed and the potential protein dosage threshold not probed yet. By selecting the receptor binding domain (RBD) from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein as a model protein and using a mouse lab model, we have explored the toxicity of RBD-made secretory granules at increasing doses up to ∼100 mg/kg of animal weight. By monitoring body weight and biochemical blood markers and through the histological scrutiny of main tissues and organs, we have not observed systemic toxicity. Otherwise, the bioavailability of the material was demonstrated by the induction of specific antibody responses. The presented data confirm the intrinsic biosafety of artificial secretory granules made by recombinant proteins and prompt their further clinical development as self-contained and dynamic protein reservoirs.

Subjects

MeSH terms (MEDLINE)

Containment of BiohazardsCOVID-19AnimalsHumansDelayed-Action PreparationsSARS-CoV-2Prostheses and ImplantsDisease Models, Animal

Author keywords

drug deliveryprotein engineeringprotein materialsrecombinant proteinself-assembling

Substances

Delayed-Action Preparations

Authors and institutions

  • Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), 08041 Barcelona, Spain.
  • Josep Carreras Leukaemia Research Institute (IJC), 08916 Badalona, Spain.
  • CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN, ISCIII), Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
  • Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
  • Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo 05508-000, Brazil.
  • Department of Pathology, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.

ORCID profiles: Eloi Parladé, Antonio Villaverde

Funding

  • Agencia Estatal de Investigación
  • Ministerio de Ciencia e Innovación
  • Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina
  • Agència de Gestió d'Ajuts Universitaris i de Recerca
  • Centres de Recerca de Catalunya
  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • Instituto de Salud Carlos III
  • Institució Catalana de Recerca i Estudis Avançats

Cite

APA

Álamo, P., Parladé, E., Favaro, M. T. P., Gallardo, A., Mendoza, R., Ferreira, L. C. S., Roher, N., Mangues, R., Villaverde, A., & Vázquez, E. (2023). Probing the Biosafety of Implantable Artificial Secretory Granules for the Sustained Release of Bioactive Proteins. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.3c08643

Vancouver

Álamo P, Parladé E, Favaro MTP, Gallardo A, Mendoza R, Ferreira LCS, et al. Probing the Biosafety of Implantable Artificial Secretory Granules for the Sustained Release of Bioactive Proteins. ACS Applied Materials & Interfaces. 2023. doi:10.1021/acsami.3c08643

BibTeX
@article{lamo2023,
  author = {Álamo, Patricia and Parladé, Eloi and Favaro, Marianna T P and Gallardo, Alberto and Mendoza, Rosa and Ferreira, Luís C S and Roher, Nerea and Mangues, Ramón and Villaverde, Antonio and Vázquez, Esther},
  title = {Probing the Biosafety of Implantable Artificial Secretory Granules for the Sustained Release of Bioactive Proteins},
  journal = {ACS Applied Materials & Interfaces},
  year = {2023},
  doi = {10.1021/acsami.3c08643}
}
Start for free →